1. Italian Association for the Study of the Liver (AISF) . AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis 2017; 49: 471–483.
Google Scholar | Crossref | Medline2. Erre, GL, Piga, M, Fedele, AL, et al. Prevalence and determinants of peripheral microvascular endothelial dysfunction in rheumatoid arthritis patients: a multicenter cross-sectional study. Mediators Inflamm 2018; 2018: 6548715.
Google Scholar | Crossref | Medline3. Erre, GL, Buscetta, G, Paliogiannis, P, et al. Coronary flow reserve in systemic rheumatic diseases: a systematic review and meta-analysis. Rheumatol Int 2018; 38: 1179–1190.
Google Scholar | Crossref | Medline4. Erre, GL, Piras, A, Mura, S, et al. Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: a case–control study. J Int Med Res 2016; 44: 76–80.
Google Scholar | SAGE Journals | ISI5. Kremer, JM, Kaye, GI, Kaye, NW, et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Follow-up over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995; 38: 1194–1203.
Google Scholar | Crossref | Medline6. Kremer, JM, Alarcón, GS, Lightfoot, RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316–328.
Google Scholar | Crossref | Medline7. Gremese, E, Ferraccioli, G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011; 10: 582–589.
Google Scholar | Crossref | Medline8. Rau, R, Pfenninger, K, Boni, A. Proceedings: liver function tests and liver biopsies in patients with rheumatoid arthritis. Ann Rheum Dis 1975; 34: 198–199.
Google Scholar | Crossref | Medline | ISI9. Quintin, E, Scoazec, J-Y, Marotte, H, et al. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 2010; 12: R143.
Google Scholar | Crossref | Medline10. Ursini, F, Russo, E, Mauro, D, et al. Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. Eur J Clin Invest 2017; 47: 728–735.
Google Scholar | Crossref | Medline11. Giles, JT, Bathon, J. Hepatic steatosis in rheumatoid arthritis: associations with disease characteristics, pharmacotherapies, and atherosclerosis. Arthritis Rheum 2012; 64: S1048.
Google Scholar12. Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–2581.
Google Scholar | Crossref | Medline13. Erre, GL, Cadoni, ML, Meloni, P, et al. Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients : a cross-sectional controlled study with real-time two-dimensional shear wave. Eur J Intern Med 2019; 69: 57–63.
Google Scholar | Crossref | Medline14. Yajima, Y, Ohta, K, Narui, T, et al. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139: 43–50.
Google Scholar | Crossref | Medline15. Caturelli, E, Squillante, MM, Andriulli, A, et al. Hypoechoic lesions in the ‘bright liver’: a reliable indicator of fatty change. A prospective study. J Gastroenterol Hepatol 1992; 7: 469–472.
Google Scholar | Crossref | Medline16. Lazo, M, Hernaez, R, Eberhardt, MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol 2013; 178: 38–45.
Google Scholar | Crossref | Medline | ISI17. von Elm, E, Altman, DG, Egger, M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–349.
Google Scholar | Crossref | Medline | ISI18. Wagan, AA, Bhutoo, AQ, Khan, D, et al. Fatty liver in Pakistani cohort with rheumatoid arthritis. Pak J Med Sci 2020; 36: 723–728.
Google Scholar | Crossref | Medline19. Iqbal, U, Perumpail, B, Akhtar, D, et al. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Medicines 2019; 6: 41.
Google Scholar | Crossref20. Kramer, HR, Fontaine, KR, Bathon, JM, et al. Muscle density in rheumatoid arthritis: associations with disease features and functional outcomes. Arthritis Rheum 2012; 64: 2438–2450.
Google Scholar | Crossref | Medline21. George, MD, Baker, JF. The obesity epidemic and consequences for rheumatoid arthritis care. Curr Rheumatol Rep 2016; 18: 6–9.
Google Scholar | Crossref | Medline22. Baker, JF, Von Feldt, J, Mostoufi-Moab, S, et al. Deficits in muscle mass, muscle density, and modified associations with fat in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66: 1612–1618.
Google Scholar | Crossref | Medline23. Gremese, E, Carletto, A, Padovan, M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013; 65: 94–100.
Google Scholar | Crossref24. Selmi, C, De Santis, M, Gershwin, ME. Liver involvement in subjects with rheumatic disease. Arthritis Res Ther 2011; 13: 226.
Google Scholar | Crossref | Medline25. Mangoni, AA, Zinellu, A, Sotgia, S, et al. Protective effects of methotrexate against proatherosclerotic cytokines: a review of the evidence. Mediators Inflamm 2017; 2017: 9632846.
Google Scholar | Crossref | Medline26. Mangoni, AA, Tommasi, S, Zinellu, A, et al. Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. Drugs Context 2018; 7: 212557.
Google Scholar | Crossref | Medline27. Bridges, SL, Alarcón, GS, Koopman, WJ. Methotrexate-induced liver abnormalities in rheumatoid arthritis. J Rheumatol 1989; 16: 1180–1183.
Google Scholar | Medline28. Richard, S, Guerret, S, Gerard, F, et al. Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology (Oxford) 2000; 39: 50–54.
Google Scholar | Crossref | Medline | ISI29. Rahimi, L, Rajpal, A, Ismail-Beigi, F. Glucocorticoid-induced fatty liver disease. Diabetes Metab Syndr Obes 2020; 13: 1133–1145.
Google Scholar | Crossref | Medline30. Tilg, H, Diehl, AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Eng J Med 2000; 343: 1467–1467.
Google Scholar | Crossref | Medline | ISI31. Satapathy, SK, Garg, S, Chauhan, R, et al. Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1946–1952.
Google Scholar | Crossref | Medline | ISI32. Li, Z, Yang, S, Lin, H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343–350.
Google Scholar | Crossref | Medline33. Feagins, LA, Flores, A, Arriens, C, et al. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol 2015; 27: 1154–1160.
Google Scholar | Crossref | Medline34. Hernaez, R, Lazo, M, Bonekamp, S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082–1090.
Google Scholar | Crossref | Medline | ISI35. Ferraioli, G, Monteiro, LBS. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 2019; 25: 6053–6062.
Google Scholar | Crossref | Medline